A Feature on M&A, VC investment, licensing and partnerships in the radiopharmaceuticals arena.
According to Evaluate, the global pharma market is forecast to reach $1.7 trillion by 2030, driven by the launch of new modalities and technologies including antibody-drug conjugates (ADCs), multi-specific antibodies, RNA-based therapies, gene/cell therapies, and radiopharmaceuticals. The global market for radiopharmaceuticals is expanding rapidly, with estimates suggesting it could reach $10.5 billion by 2026.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze